Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02869789 · ClinicalTrials.gov registry record · Phase 4
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
A Phase 4 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,041
- Enrollment target
NCT02869789 is a Phase 4 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,041 participants.
The verdict
NCT02869789, a Phase 4 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,041 participants
- Enrollment target
Study Summary
A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.
Interventions
- DRUG Nivolumab in combination with Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,041 participants |
| Start Date | 2016-10-05 |
| Est. Completion | 2022-05-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02869789
The ClinicalTrials.gov registry entry for NCT02869789 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,041 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nivolumab in combination with Ipilimumab is the first listed.
NCT02869789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02869789 about?
NCT02869789 is a clinical study titled "An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers". A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.
What is the current status of trial NCT02869789?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,041 participants. The study started on 2016-10-05. Estimated completion is 2022-05-13.
What interventions are being tested in trial NCT02869789?
The interventions under investigation include: Nivolumab in combination with Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02869789?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.